In BRAF-mutant melanoma, treatment with BRAF inhibitors initially inhibits ERK signaling, followed by a rebound activation of ERK signaling as negative feedback pathways are disrupted (Lito et al., 2012). This evidence concerns the gene BRAF and melanoma.